FDA approves Merck, Eisai’s Keytruda and Lenvima combination for endometrial cancer
Merck and Eisai have secured approval from the US Food and Drug Administration (FDA) for Keytruda (pembrolizumab) plus Lenvima (lenvatinib) combination to treat patients with certain types of